Sound news from Silence, a good diagnosis for IDH, and Cello make the right sounds.
The volatilities continue… last week saw the ups and downs that have been plaguing the markets for a while now, with the FTSE 100 closing some 80 points down than at the start of the week, and the AIM All share closing some 5 points higher. Greek and Italian debt issues continue to be a sore point, which the markets continue to ponder widely on, and this week has continued the theme. UK CPI inflation for August rose to 4.5% from 4.4% in July, and there was an increase in Italy’s borrowing costs on five-year bonds to 5.6%, up from 4.93% due to a lack of investor confidence in finances, whilst the US markets saw the unveiling of a $450bn package of tax cuts and spending plans aimed at creating jobs and boosting the economy. The week ahead sees average weekly earnings and unemployment data being announced in the UK, together with retail sales data.
Abcam (LON:ABC) (ABC 351.25p / £638.31m)
Abcam makes sources and cells protein research tools, which are used for studying proteins at a cellular level. The Company’s vision is to become the world’s leading supplier of protein research tools. The Company has just released its interim results. Abcam’s range of products continue to grow, as does the Company’s sales momentum. Sales are up by 17.1 per cent and the Company’s product range has grown by 16.9 per cent in 2011. The Company has made two successful acquisitions, which have broadened the product portfolio. In May 2011, the Company acquired MitoSciences Inc for $6m, which is aimed to expanding Abcam’s presence in the antibodies field. Yesterday, the Company closed its acquisition of Ascent Scientific Ltd, a Bristol based research company for £10m, which will provide Abcam with access to a new market in small molecules and biochemicals. Though the Company faces challenges as a result of reduced public spending in some countries, growth in China and Japan have ensured growth and international expansion.
Alliance Pharma (LON:APH) (APH 30.5p /£73.02m)
A week for interim results- the specialty pharma company announced figures for the 6 months to 30 June 2011, highlights of which include £1m growth in both revenue and profit before tax to £24.4m and £7m respectively, as well as…
